US biomedical manufacturer Aldevron has completed the production and delivery of a DNA-based vaccine to combat malaria for the Naval Medical Research Center (NMRC).
The company has manufactured three plasmid DNA constructs, which will be evaluated in a Phase I/II challenge study, as part of a contract with NMRC.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Malaria is a mosquito-borne infectious disease that can sometimes prove fatal for human lives. Mosquitoes from the Anopheles genus transmit the disease.
Under the contract, Aldevron made use of its proprietary large-scale DNA production technology to manufacture gram quantities of plasmid DNA under cGMP conditions.
Aldevron CEO Michael Chambers said: “Malaria is a difficult problem from medical and socioeconomic perspectives. It is a great privilege to be a part of this project.”
Commenting on the achievement, Aldevron CSO John Ballantyne said that the company has been working on improving its manufacturing techniques, quality systems and scale over the years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBallantyne said: “These improvements have allowed the company to support the tremendous growth in plasmid DNA, mRNA, and proteins that are being developed to address a large number of diseases with severe unmet medical needs.”
A WHO estimate states that approximately 3.2 billion people are at risk of malaria. An estimated 214 million malaria cases and some 438,000 malaria deaths were recorded last year.
In addition to DNA vaccines, Aldevron produces the critical components for gene editing, gene therapy and cell therapies, including treatments using chimeric antigen receptor T-cells (CAR-T).
